



Cat. No.: BRB028 (16 ml Ready-to-use)

Instructions for use

Intended use

This antibody is designed for the specific localisation of CDX2 in formalin-fixed, paraffin-embedded tissue sections. . Anti-CDX2 antibody is intended for in vitro diagnostic use.

Specifications

Specificity:Human CDX2Clone:EPR2764YIsotype:Rabbit IgG

Species reactivity: Human +, others not tested

Summary and Description

CDX2 is a transcription factor which regulates proliferation and differentiation of intestinal mucosa. In adults the expression of CDX2 is usually limited to intestinal epithelium. Immunohistochemically, the protein is detectable in nuclei of normal intestinal epithelium. Loss of CDX2 correlates with loss of differentiation in colorectal tumours. Anti-CDX2 antibody is very useful in identifying the origin of metastatic adenocarcinomas and carcinoids. Some mucinous carcinomas of the ovary also stain positive with this CDX2 antibody as well as some carcinomas from the upper gastroinstestinal tract (see Moskaluk *et al.* 2003).

Reagent provided

Rabbit polyclonal antibody in buffer with carrier protein and preservative for stabilisation in the following formats:

Ready-to-use: 16 ml (Cat. No. BRB028)

Dilution of primary antibody

None

Storage and handling

The antibody should be stored at 2-8°C without further dilution.

Dilutions of the concentrated antibody should be done in a suitable antibody dilution buffer (e.g. ZUC025 from Zytomed Systems). The diluted antibody should be stored at 2-8°C after use. The stability of this working solution depends on various parameters and has to be confirmed by appropriate controls.

The antibody provided is suitable for use until the expiry date indicated on the label, if stored at 2-8°C. Do not use product after the expiry date. Positive and negative controls should be run simultaneously with all specimens. If unexpected staining is observed which cannot be explained by variations in laboratory procedures and a problem with the antibody is suspected, contact Zytomed Systems' technical support or your local distributor.

Precautions

Use through qualified personnel only. Wear protective clothing to avoid contact of reagents and specimens with eye, skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with large amounts of water.

Microbial contamination of the reagent must be avoided, since otherwise non-specific staining may occur. ProClin300 and sodium azide (NaN₃) are used for stabilisation. Reaction of sodium azide with lead or copper in drainage pipes can result in the formation of highly explosive metallic azides. Discard the antibody solution in a large volume of running water to avoid formation of deposits. A material safety data sheet (MSDS) for the pure substances is available upon request.

Date of approval: 2023-03-08 Revision: V01 Page **1** of **2**

Staining procedure

Refer to the following table for conditions specifically recommended for this antibody. Also refer to detection system data sheets for guidance on specific staining protocols or other requirements.

<u>Parameter</u> <u>Zytomed Systems recommendations</u>

* Pre-treatment Heat Induced Epitope Retrieval (for example in Citrate Buffer pH 6.0)

* Control tissue Colon carcinoma or normal colon mucosa

* Working dilution None
* Incubation time 60 minutes

Quality control

The recommended positive control tissues for this antibody are colon carcinoma or normal colon mucosa. We recommend carrying out a positive and a negative control with every staining run. Please refer to the instructions of the detection system for guidance on general quality control procedures.

Troubleshooting

If you observe unusual staining or other deviations from the expected results please read these instructions carefully, refer to the instructions of the detection system for relevant information or contact your local distributor.

Expected results

This antibody stains positive in the nuclei of epithelial cells of intestinal tissue in formalin-fixed, paraffin-embedded tissue sections. Interpretation of the staining results is solely the responsibility of the user. Any experimental result should be confirmed by a medically established diagnostic procedure.

Limitations of the Procedure

Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining, for example variations in fixation and embedding or the inherent nature of the tissue can cause inconsistent results (Nadji and Morales, 1983). Endogenous peroxidase, pseudoperoxidase activity in erythrocytes or biotin may cause non-specific staining depending on the detection system used. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive results with HRP (horse radish peroxidase) detection systems (Omata *et al*, 1980). Inadequate counterstaining and mounting can influence the interpretation of the results.

Zytomed Systems warrants that the product will meet all requirements described from its shipping date until the expiry date is reached, if the product is stored and utilised as recommended. No additional guarantees can be given. Under no circumstances shall Zytomed System be liable for any damages arising out of the use of the reagent provided.

Performance characteristics

Zytomed Systems has conducted studies to evaluate the performance of the antibody for use with a standard detection system. The product has been found to be sensitive and specific to the antigen of interest with minimal or no cross-reactivity.

Bibliography

Levine PH et al. Diagn Cytopathol 2006; 34:191-195 De Lott LB et al. Arch Pathol Lab Med 2005; 129:1100-1105 Moskaluk CA et al. Mod Pathol 2003; 16:913-919 Hinoi T et al. Am J Pathol 2001; 159:2239-2248 Omata M et al. Am J Clin Pathol 1980; 73: 626-632 Mazziotta, RM et al. AIMM 13,1 (2005): 55-60 Saqi, Ai et al. Am J Clin Path. 123,3 (2005): 394-404 Werling, RW et al. Am J Surg Path 27,3 (2003): 303-10 Saad RS et al. Am J Clin Pathol 2004; 122:421-427 Werling RW et al. Am J Surg Pathol 2003; 27:303-310 Bai YQ et al. Cancer Letters 2002; 176:47-55 Giordano TJ et al. Am J Pathol 2001; 159:1231-1238 Nadji M and Morales AR. Ann N.Y. Acad Sci 1983; 420:134-139 Erickson, LA et al. Endocrine pathology 15,3 (2004): 247-52 Kaimaktchiev, V et al. Modern pathology 17,11 (2004): 1392-9



www.zytomed-systems.de
Zytomed Systems GmbH • Anhaltinerstraße 16 • 14163 Berlin, Germany • Tel: (+49) 30-804 984

Explanations of the symbols on the product label

Symbols are used in accordance with ISO 15223-1. Further symbols on the product label might be:



GSH07: Warning / Attention

For Research Use Only

Date of approval: 2023-03-08 Revision: V01 Page 2 of 2